The American Academy of Neurology (AAN) Annual Meeting brings together an international attendance of the neurology committee to promote the highest quality patient-centered neurologic care, convey the latest advances, and enhance career satisfaction.
Episode 61: 2022 AAN Annual Meeting HighlightsApril 9th 2022
Mind Moments®, a podcast from NeurologyLive®, brings you exclusive interviews with Jennifer Frontera, MD; Stephen Krieger, MD; Peter McAllister, MD; Kelly Knupp, MD, MSCS; Bruce Cree, MD, PhD, MAS; Shrujal Baxi, MD, MPH; and Indu Subramanian, MD. [LISTEN TIME: 32 minutes]
Long-Term Advantages of Fenfluramine for Lennox-Gastaut Syndrome: Kelly Knupp, MDApril 8th 2022
The pediatric neurologist and epilepsy specialist at Colorado Children’s Hospital discussed new data presented at AAN 2022 on the use of recently approved fenfluramine in patients with Lennox-Gastaut syndrome. [WATCH TIME: 3 minutes]
Ubrogepant Demonstrates Several Positive Real-World Migraine Impacts in Patients With Prior Treatment FailureApril 7th 2022
Following the switch to ubrogepant, more than half of patients with migraine had reduced use of triptans and more than one-third of patients had reduced use of anti-inflammatory drugs.
The Therapeutic Advances in Efficacy for NMOSD: Bruce Cree, MD, PhD, MAS, FAANApril 7th 2022
The clinical research director of the UCSF Multiple Sclerosis Center offer his perspective on the 3 available agents for the treatment of patients with neuromyelitis optica spectrum disorder. [WATCH TIME: 2 minutes]
Understanding the Relationship Between Cerebral Arterial Blood Flow and Serum Neurofilament Light in MSApril 7th 2022
Dejan Jakimovski, MD, PhD, research assistant professor, Buffalo Neuroimaging Analysis Center, discussed his presentation at AAN 2022 on the associations between cerebral hypoperfusion and increased axonal pathology in MS.
Comparing Neurological Examinations of COVID-19 With Other Viral Infections: Matthew Schindler, MD, PhDApril 7th 2022
The assistant professor of neurology at the University of Pennsylvania discussed the similarities observed between the results of neurological exams in patients with COVID-19 vs other respiratory infections. [WATCH TIME: 3 minutes]
Improving Care for Adults With Intellectual and Developmental DisabilitiesApril 7th 2022
Seth M. Keller, MD, chair of the Section for Adults With IDDs at AAN, shared his perspective on the state of care for these individuals and the need to improve the difficulties they face when transitioning out of pediatric care.
SB623’s Potential for Traumatic Brain Injury: Peter J. McAllister, MD, FAANApril 6th 2022
The medical director and chief medical officer of the New England Center for Neurology and Headache spoke to the phase 2 STEMTRA trial results of the stem cell treatment SB623. [WATCH TIME: 4 minutes]
GammaCore Noninvasive Vagus Nerve Stimulation Demonstrates Safety, Feasibility in Acute StrokeApril 6th 2022
All patients received 100% of the intended stimulations, with no reported deaths, stimulation site reactions, or any cases of acute coronary syndrome or symptomatic intracerebral hemorrhage.
Patients With Narcolepsy Prefer Once-Nightly FT218 Over Twice-Nightly Sodium Oxybates, Data SuggestsApril 6th 2022
Among those who took their second nighttime sodium oxybate dose 4 hours after their first, 42% claimed they felt somewhat, quite a bit, or extremely groggy or unsteady the next morning.
RISE-PD Study of IPX-203 in Parkinson Disease: Robert A. Hauser, MD, MBAApril 6th 2022
The director of the Parkinson’s Disease and Movement Disorder Center at the University of South Florida detailed the data presented at AAN 2022 and IPX-203’s potential in Parkinson disease. [WATCH TIME: 3 minutes]
NeuroVoices: Elia Pestana-Knight, MD, on the Importance of Ganaxolone’s Approval in CDDApril 6th 2022
The pediatric epileptologist at Cleveland Clinic’s Epilepsy Center discussed data presented at AAN 2022 on the use of ganaxolone in CDD, as well as how its recent approval sets the stage for the future.
Combination Agent P2B001 Shows Promise for Parkinson Disease in Phase 3 DataApril 5th 2022
The Pharma Two B therapy combines a dopamine agonist, pramipexole, and an MAO-B inhibitor, rasagiline, and has shown significant improvements on UPDRS total scores and ESS scores for untreated patients with PD.
Ocrelizumab Shows Improved Cognition, Low Disease Activity in Progressive MS Interim DataApril 5th 2022
One-year data from the single-arm phase 3b CONSONANCE trial (NCT03523858) suggest that the Genentech agent (Ocrevus) resulted in low levels of disease activity and improved cognitive performance in those with secondary and primary progressive multiple sclerosis.
Targeting Senescent Cells to Address Alzheimer Disease and NeurodegenerationApril 4th 2022
In an AAN 2022 Hot Topics plenary session, Miranda E. Orr, PhD, highlighted the potential of targeting senescent cells with senolytics as a therapeutic approach to age-related diseases such as Alzheimer disease, and detailed the ongoing phase 2 SToMP-AD clinical trial (NCT04685590).
Understanding Long-Term Neurological Trajectories in Severe COVID-19 Cases: Jennifer Frontera, MDApril 4th 2022
The professor of neurology at NYU Langone Grossman School of Medicine discussed her talk at AAN 2022 on neurological sequelae and follow-up in hospitalized and nonhospitalized patients with COVID-19. [WATCH TIME: 8 minutes]
Inebilizumab’s Efficacy in Patients With NMOSD Early in Disease Course: Bruce Cree, MD, PhD, MAS, FAANApril 4th 2022
The clinical research director of the UCSF Multiple Sclerosis Center discussed new data presented at AAN on inebilizumab (Uplizna; Horizon) in neuromyelitis optica spectrum disorder. [WATCH TIME: 4 minutes]
The Paradigm Shift in Therapeutic Intervention for ALS: Matthew Kiernan, MBBS, PhD, DSc, FRACP, FAHMSApril 3rd 2022
The Bushell Chair of Neurology at the University of Sydney offered his perspective on phase 2 data of CNM-Au8 in amyotrophic lateral sclerosis and spoke to the advances that the field has made in recent years. [WATCH TIME: 3 minutes]
Next Steps in Tackling CDKL5 Deficiency Disorder Following First Approval: Elia Pestana-Knight, MDApril 3rd 2022
The pediatric epileptologist from Cleveland Clinic provided commentary on the changes needed to improve research and drug development in CDKL5 deficiency disorder, as well as the organizations committed to advancing the state of care. [WATCH TIME: 3 minutes]